A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiative
Haemophilia · 2024
DOI: 10.1111/hae.15122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2024. Verfasst von Elizabeth Clearfield und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Policy Advancement Ltd, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: von Willebrand Diseases, Delphi Technique. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Star Therapeutics, Band Therapeutics, BioMarin Pharmaceutical.
Abstract (Originalsprache)
Introduction
Treatment options are expanding for von Willebrand disease (VWD). A core outcome set (COS)—a minimum set of agreed‐upon outcomes to be used in every clinical trial for a given condition—provides guidance on which outcomes are most important to measure to ensure necessary data is collected for a variety of stakeholders and enable comparison across products and trials. Aim coreVWD aimed to develop a COS for trials for prophylaxis and perioperative treatments for VWD.
Methods
A modified Delphi consensus process was used to condense/prioritize a long list of potential outcomes. Over three Delphi rounds, a multi‐stakeholder panel (patients, clinicians, pharmaceutical company representatives, HTA organizations, payer, and government organization representatives) rated each outcome from 1 (not important to include in a COS) to 9 (essential to include). Outcomes were eliminated or retained based on pre‐determined criteria; a special provision to elevate patient priorities was included. An in‐person consensus meeting was held after Delphi round 2.
Results
Thirty‐nine panellists participated. The final COS for prophylaxis treatment included 18 outcomes, seven of which are part of a special subset selected for women, girls and people with the potential to menstruate. There were 11 outcomes in the final perioperative branch COS. Six outcomes overlapped both COS.
Conclusions
The coreVWD COS represents a consensus list of outcomes for clinical trials for both factor and non‐factor VWD therapies. These outcomes will be useful across the lifecycle of a product, from clinical development through regulatory and market access phases and into patient‐provider decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Policy Advancement Ltd, Washington, District of Columbia, USA.
- Vega Therapeutics Inc, South San Francisco, USA.
- Canadian Hemophilia Society, Montreal, Canada.
- Department of Medicine, Brigham and Women's Hospital, Boston, USA.
- Department of Medicine, Harvard Medical School, Boston, USA.
- National Bleeding Disorders Foundation, New York, USA.
ORCID-Profile: Elizabeth Clearfield, Nathan T Connell, Maria E Santaella, Michelle Lavin, Dawn Rotellini, Mark W Skinner
Förderung
- Star Therapeutics
- Band Therapeutics
- BioMarin Pharmaceutical
- Takeda Pharmaceuticals
- F. Hoffmann-La Roche AG
Zitieren
APA
Clearfield, E., Kim, B., Ford, S., Connell, N. T., Santaella, M. E., Lavin, M., Degenaar-Dujardin, M. E. L., Ayoub, E., Flood, V. H., Rotellini, D., Skinner, M. W., James, P., & coreVWD Panel (2024). A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiative. Haemophilia. https://doi.org/10.1111/hae.15122
Vancouver
Clearfield E, Kim B, Ford S, Connell NT, Santaella ME, Lavin M, et al. A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiative. Haemophilia. 2024. doi:10.1111/hae.15122
BibTeX
@article{Clearfield2024,
author = {Clearfield, Elizabeth and Kim, Benjamin and Ford, Sarah and Connell, Nathan T and Santaella, Maria E and Lavin, Michelle and Degenaar-Dujardin, Manon E L and Ayoub, Emily and Flood, Veronica H and Rotellini, Dawn and Skinner, Mark W and James, Paula and coreVWD Panel, coreVWD Panel},
title = {A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiative},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.15122}
}
EUVIMED